• In February 2026, Medpace Holdings reported past fourth-quarter 2025 results showing revenue of US$708.45 million and GAAP diluted EPS of US$4.67, alongside full-year 2025 revenue of US$2.53 billion and net income of US$451.12 million.
• The company also issued 2026 guidance calling for revenue of US$2.76–US$2.86 billion and GAAP diluted EPS of US$16.68–US$17.50, while acknowledging elevated trial cancellations and a softer book-to-bill ratio despite strong new business awards.
• We’ll now examine how Medpace’s elevated cancellations but still robust 2026 revenue and earnings guidance shape its broader investment narrative.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Medpace Holdings Investment Narrative Recap

To own Medpace, you generally need to believe in sustained demand for outsourced clinical trials and the company’s ability to convert its backlog into profitable work. The key near term catalyst is how quickly bookings and backlog recover after fourth quarter cancellations pushed the book to bill ratio down to 1.04x. Right now, the biggest risk is that elevated cancellations and softer biotech funding persist and weigh on future revenue visibility. The new 2026 guidance does not remove that risk.

The most relevant new data point is Medpace’s 2026 outlook, which calls for revenue of US$2.76–US$2.86 billion and GAAP diluted EPS of US$16.68–US$17.50. This guidance sits alongside higher fourth quarter cancellations and margin pressure, so it matters for how you judge whether recent weakness is a temporary bump or something more durable. For many investors, the tension between that guidance and the soft book to bill is now central to the Medpace story.

Yet even with robust guidance, investors should be aware that elevated cancellations and a softer book to bill could still...

Medpace Holdings' narrative projects $3.1 billion revenue and $526.6 million earnings by 2028. This requires 11.8% yearly revenue growth and about a $108 million earnings increase from $418.3 million today.

Uncover how Medpace Holdings' forecasts yield a $545.75 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Before this report, the most optimistic analysts were modeling about US$3.5 billion of revenue and US$563.5 million of earnings by 2028, assuming strong backlog conversion despite client concentration risk. You can see how their upbeat view contrasts with the more cautious read of today’s cancellations and softer book to bill, and it is a good reminder that your own expectations may diverge meaningfully from both sets of pre news assumptions.

Explore 12 other fair value estimates on Medpace Holdings - why the stock might be worth as much as 69% more than the current price!

Build Your Own Medpace Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Medpace Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Medpace Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medpace Holdings' overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Outshine the giants: these 28 early-stage AI stocks could fund your retirement.
• Find 53 companies with promising cash flow potential yet trading below their fair value.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.